Abstract

Fortive Corporation will report second-quarter 2026 results on July 29, 2026 Pre-MKt, with current market consensus pointing to revenue of 1.07 billion US dollars, adjusted EPS of 0.71 US dollars, and EBIT of 265.62 million US dollars, all implying year-over-year growth.

Market Forecast

Markets anticipate Fortive Corporation to deliver revenue of 1.07 billion US dollars this quarter, up 5.48% year over year, alongside adjusted EPS of 0.71 US dollars, up 19.38% year over year, and EBIT of 265.62 million US dollars, up 13.34% year over year. Forecasts do not include specific guidance for gross profit margin or net margin, but a richer mix of software and services is expected to underpin profitability resilience. The main business is expected to see steady demand across software-enabled instrumentation and asset lifecycle solutions, with a constructive outlook on recurring revenue and price realization. The most promising segment is Advanced Healthcare Solutions, which generated 326.20 million US dollars last quarter; as a reference, it grew 1.20% year over year in fiscal year 2025 as scale in software and services continued to improve.

Last Quarter Review

Fortive Corporation’s previous quarter delivered revenue of 1.07 billion US dollars (down 27.46% year over year), a gross profit margin of 63.17%, GAAP net profit attributable to the parent company of 136.00 million US dollars, a net profit margin of 12.75%, and adjusted EPS of 0.70 US dollars (down 17.65% year over year). A key highlight was that both revenue and adjusted EPS exceeded market expectations, with EBIT at 272.80 million US dollars surpassing the estimate, while GAAP net profit decreased 26.55% sequentially. By segment, Intelligent Operating Solutions contributed 743.20 million US dollars and Advanced Healthcare Solutions 326.20 million US dollars, with total company revenue declining 27.46% year over year amid portfolio changes and tough comparisons following the separation of Precision Technologies.

Current Quarter Outlook

Intelligent Operating Solutions

Intelligent Operating Solutions remains the core earnings engine, and this quarter’s setup appears grounded in steady end-market activity for instrumentation, gas detection, and facility and asset lifecycle software. The combination of higher software and subscription penetration at brands such as Accruent and continued demand for compliance, asset performance, and safety-related solutions can support durability in both revenue and margin. Recent steps to enhance the value proposition, including the partnership to integrate AI-driven energy analytics into Accruent’s tower management platform, aim to improve attach rates and expand analytics offerings, potentially supporting new wins and upsell opportunities. Pricing discipline and a favorable mix shift toward services, software, and recurring revenue should help defend gross margins even if certain hardware volumes remain mixed. Assuming normal seasonality and order conversion, IOS is positioned to contribute the majority of earnings growth, with execution on software pipeline, renewals, and cross-sell initiatives as key levers for this quarter’s results.

Advanced Healthcare Solutions

Advanced Healthcare Solutions has emerging catalysts that could make it the faster-growing business in the near term, particularly as the portfolio skews further toward consumables, services, and software. The unit’s recent acquisition activity, including the advanced disinfection stake in UV Smart, expands the technology set and broadens the clinical infection-prevention portfolio, which can deepen customer relationships and increase recurring revenue contributions. The business also benefits from secular needs around sterile processing, workflow digitization, and compliance, which align with hospital priorities to improve safety and productivity. While certain equipment categories have faced uneven demand due to policy shifts, the mix of dosimetry services, healthcare software, and expanding solutions in advanced sterilization can provide ballast and potential upside if procurement improves. With last quarter’s revenue at 326.20 million US dollars and fiscal-year 2025 growth of 1.20%, this quarter’s watch items include order momentum for high-return sterilization solutions, service attach rates, and early synergy or channel leverage from recent investments.

Key Stock Price Drivers This Quarter

The stock’s near-term performance is likely to hinge on the quality of earnings versus the headline beats. The market will focus on the sustainability of gross margin against mix changes and measured hardware demand, as well as conversion of software pipelines and the rate of recurring revenue growth. Any commentary on order intake, backlog health, and renewal rates within the software franchises is set to carry outsized weight for the valuation. Capital deployment remains an active support: the expansion of the share repurchase authorization to 20 million shares and the maintenance of the quarterly dividend demonstrate confidence in cash generation, and these actions can offset volatility around growth. Balance sheet flexibility was reinforced by the 1.10 billion US dollars senior notes issuance to refinance the 2026 maturity, which stabilizes near-term funding needs at known rates and helps maintain optionality for bolt-on deals. Finally, management’s full-year adjusted EPS framework of 2.90 to 3.00 US dollars, reiterated earlier this year, sets a reference point; investors will parse whether second-quarter results and commentary keep the company on track for the high end of that range or suggest a more balanced cadence through the back half of the year.

Analyst Opinions

Bullish perspectives modestly outweigh bearish ones among directionally explicit views published since January 2026, with approximately three constructive/bullish takes versus two cautious/bearish previews and ratings. Supportive views emphasize improving earnings quality from a growing software and services mix, the durability of margins, and capital deployment that underpins shareholder returns even as industrial demand varies across categories. Argus upgraded Fortive Corporation to Buy with a 68 US dollars price target, citing improved visibility into recurring revenue and a favorable setup for operating leverage as software scales. Baird maintained an Outperform rating and lifted its target to 70 US dollars, pointing to steady execution in Intelligent Operating Solutions and incremental expansion opportunities in healthcare, including benefits from recent portfolio additions. A late-July institutional preview framed this quarter’s setup as positive, highlighting the 5.48% year-over-year revenue growth expectation, 19.38% year-over-year EPS growth, and 13.34% year-over-year EBIT growth, with commentary that a higher share of software and subscription revenue should bolster gross margin stability. The bullish camp also notes that debt refinancing reduces near-term balance-sheet uncertainty and that the expanded buyback provides another lever to smooth EPS trajectory while maintaining M&A capacity. In interpreting mixed signals from other coverage—such as underweight or cautious stances focusing on valuation or pockets of soft hardware demand—the constructive side argues that the portfolio composition changes over the last year leave the company less exposed to single end-markets and better positioned to compound through price, productivity, and recurring revenue scale. For this quarter specifically, bulls expect revenue to meet or modestly exceed the 1.07 billion US dollars consensus, with margins defended by mix and pricing, and look for confirmation in order and renewal commentary to sustain confidence in the full-year EPS framework of 2.90 to 3.00 US dollars. They also expect additional color on integration progress and cross-sell potential from software and healthcare additions, which would support the case for continued high-quality cash generation and disciplined capital allocation through the remainder of 2026.